PCSK9 medication plus statin may help lower cholesterol after heart transplant
Research Highlights:
The cholesterol-lowering medication alirocumab, a PCSK9 inhibitor, along with a statin, lowered LDL cholesterol levels more than 50% in patients after a heart transplant, compared to those taking a placebo plus statin, according to the results of a new clinical trial.
Researchers found alirocumab did not reduce the risk of developing cardiac allograft vasculopathy, a progressive coronary artery disease that occurs after a heart transplant.
Note: This trial is simultaneously published today as a full manuscript in the peer-reviewed scientific journal Circulation.
Embargoed until 10:00 a.m. CT/11:00 a.m. ET, Monday, Nov. 10, 2025
NEW ORLEANS, Nov. ...